US2004014987A1PendingUtilityA1
Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases
Assignee: GEMIN X BIOTECHNOLOGIES INCPriority: Jan 26, 2000Filed: Mar 19, 2003Published: Jan 22, 2004
Est. expiryJan 26, 2020(expired)· nominal 20-yr term from priority
A61P 43/00C07D 403/14A61K 31/4025A61K 31/4439A61P 31/00A61P 35/00
44
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to novel Pyrrole-Type compounds, compositions comprising Pyrrole-Type compounds, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a composition comprising a Pyrrole-Type compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell. The present invention also relates to novel Pyrrole-Type compounds, compositions, and methods useful for treating or preventing a viral infection. The compounds, compositions, and methods of the invention are also useful for inhibiting the replication and/or infectivity of a virus.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A tartrate salt of the compound having the Formula:
2 . A compound having the Formula:
or a pharmaceutically acceptable salt thereof.
3 . The compound of claim 2 , wherein the salt is a tartrate salt.
4 . The compound of claim 1 , wherein the tartrate salt is an L-tartrate salt, a D-tartrate salt, or a D/L-tartrate salt.
5 . The compound of claim 2 , wherein the tartrate salt is an L-tartrate salt, a D-tartrate salt, or a D/L-tartrate salt.
6 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the Formula:
or a pharmaceutically acceptable salt thereof.
7 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the Formula:
or a pharmaceutically acceptable salt thereof.
8 . A method for treating cancer or neoplastic disease, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula (V):
or a pharmaceutically acceptable salt thereof, wherein, in the compound of Formula (V):
each R 1 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 3 , —CH 2 C 6 H 5 , —C(O)OC(CH 3 ) 3 , —C(O)OCH 2 C 6 H 5 , and —C(O)CH 3 ;
R 2 is selected from the group consisting of —H, C 1 -C 12 straight chain alkyl, —CH 2 C 6 H 5 , —SiR 10 R 11 R 12 , —C(O)CH 3 , —C(O)C 6 H 5 , -2-tetrahydropyranyl, —OCH 2 OCH 3 , and —C(O)OCH 2 CCl 3 ;
R 7 is selected from the group consisting of —H, C 1 -C 15 straight chain alkyl, —(CH 2 ) 9 CH═CH 2 , —(CH 2 ) 6 F, —(CH 2 ) 5 OC 6 H 5 , —(CH 2 ) 6 OH, —(CH 2 ) 7 CN, —CH 2 CH 2 C 6 H 5 , —(CH 2 ) 4 COOH, —(CH 2 ) 5 COOH, —(CH 2 ) 5 COOMe, —(CH 2 ) 11 COOH, —(CH 2 ) 12 COOH, —(CH 2 ) 12 OH, —(CH 2 ) 13 OH, —(CH 2 ) 11 CN, —(CH 2 ) 11 OC(O)NH 2 , —(CH 2 ) 11 COOEt, —C(O)(CH 2 ) 9 CH 3 , —(CH 2 ) 5 C(O)N(CH 2 CH 2 ) 2 O, C 3 -C 7 cycloalkyl, —C 6 H 5 , 2-pyrrolyl, -3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, and 3-furanyl, the phenyl being substituted with one or more halo, methyl, methoxyl, hydroxyl, methoxycarbonyl or trifluoromethyl groups;
R 8 is selected from the group consisting of —H, C 1 -C 11 straight chain alkyl, —(CH 2 ) 4 COOEt, and —C 6 H 5 ;
when R 7 is other than 2-pyrrolyl, then R 9 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 3 , and —CH 2 CH 2 CH 3 ;
when R 7 is 2-pyrrolyl, then R 9 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , and —OCH 3 ;
R 10 is selected from the group consisting of C 1 -C 4 straight or branched chain alkyl and —C 6 H 5 ;
R 11 and R 12 are independently selected from the group consisting of —CH 3 , —CH 2 CH 3 , and —C 3 H 7 ;
R 16 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 2 CH 3 , and —(CH 2 ) 6 CH 3 ; and
R 17 is selected from the group consisting of —H, —CN, —COOMe, —COOEt, and —COOH.
9 . The method of claim 8 , wherein the compound of Formula (V) has the Formula:
or a pharmaceutically acceptable salt thereof.
10 . The method of claim 8 wherein the compound of Formula (V) has the Formula:
or a pharmaceutically acceptable salt thereof.
11 . A method for inhibiting the growth of a cancer cell or neoplastic cell, comprising contacting the cancer cell or neoplastic cell with an effective amount of a compound of Formula (V):
or a pharmaceutically acceptable salt thereof, wherein, in the compound of Formula (V):
each R 1 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 3 , —CH 2 C 6 H 5 , —C(O)OC(CH 3 ) 3 , —C(O)OCH 2 C 6 H 5 , and —C(O)CH 3 ;
R 2 is selected from the group consisting of —H, C 1 -C 12 straight chain alkyl, —CH 2 C 6 H 5 , —SiR 10 R 11 R 12 , —C(O)CH 3 , —C(O)C 6 H 5 , -2-tetrahydropyranyl, —OCH 2 OCH 3 , and —C(O)OCH 2 CCl 3 ;
R 7 is selected from the group consisting of —H, C 1 -C 15 straight chain alkyl, —(CH 2 ) 9 CH═CH 2 , —(CH 2 ) 6 F, —(CH 2 ) 5 OC 6 H 5 , —(CH 2 ) 6 OH, —(CH 2 ) 7 CN, —CH 2 CH 2 C 6 H 5 , —(CH 2 ) 4 COOH, —(CH 2 ) 5 COOH, —(CH 2 ) 5 COOMe, —(CH 2 ) 11 COOH, —(CH 2 ) 12 COOH, —(CH 2 ) 12 OH, —(CH 2 ) 13 OH, —(CH 2 ) 11 CN, —(CH 2 ) 11 OC(O)NH 2 , —(CH 2 ) 11 COOEt, —C(O)(CH 2 ) 9 CH 3 , —(CH 2 ) 5 C(O)N(CH 2 CH 2 ) 2 O, C 3 -C 7 cycloalkyl, —C 6 H 5 , 2prrolyl, -3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, and 3-furanyl, the phenyl being substituted with one or more halo, methyl, methoxyl, hydroxyl, methoxycarbonyl or trifluoromethyl groups;
R 8 is selected from the group consisting of —H, C 1 -C 11 straight chain alkyl, —(CH 2 ) 4 COOEt, and —C 6 H 5 ;
when R 7 is other than 2-pyrrolyl, then R 9 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 3 , and —CH 2 CH 2 CH 3 ;
when R 7 is 2-pyrrolyl, then R 9 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , and —OCH 3 ;
R 10 is selected from the group consisting of C 1 -C 4 straight or branched chain alkyl and —C 6 H 5 ;
R 11 and R 12 are independently selected from the group consisting of —CH 3 , —CH 2 CH 3 , and —C 3 H 7 ;
R 16 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 2 CH 3 , and —(CH 2 ) 6 CH 3 ; and
R 17 is selected from the group consisting of —H, —CN, —COOMe, —COOEt, and —COOH.
12 . The method of claim 11 , wherein the compound of Formula (V) has the Formula:
or a pharmaceutically acceptable salt thereof.
13 . The method of claim 11 , wherein the compound of Formula (V) has the Formula:
or a pharmaceutically acceptable salt thereof.
14 . A method for treating a viral infection in a patient, comprising administering to a patient in need of such treatment a therapeutically effective amount of a therapeutically effective amount of a compound of Formula (V):
or a pharmaceutically acceptable salt thereof, wherein, in the compound of Formula (V):
each R 1 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 3 , —CH 2 C 6 H 5 , —C(O)OC(CH 3 ) 3 , —C(O)OCH 2 C 6 H 5 , and —C(O)CH 3 ;
R 2 is selected from the group consisting of —H, C 1 -C 12 straight chain alkyl, —CH 2 C 6 H 5 , —SiR 10 R 11 R 12 , —C(O)CH 3 , —C(O)C 6 H 5 , -2-tetrahydropyranyl, —OCH 2 OCH 3 , and —C(O)OCH 2 CCl 3 ;
R 7 is selected from the group consisting of —H, C 1 -C 15 straight chain alkyl, —(CH 2 ) 9 CH═CH 2 , —(CH 2 ) 6 F, —(CH 2 ) 5 OC 6 H 5 , —(CH 2 ) 6 OH, —(CH 2 ) 7 CN, —CH 2 CH 2 C 6 H 5 , —(CH 2 ) 4 COOH, —(CH 2 ) 5 COOH, —(CH 2 ) 5 COOMe, —(CH 2 ) 11 COOH, —(CH 2 ) 12 COOH, —(CH 2 ) 12 OH, —(CH 2 ) 13 OH, —(CH 2 ) 11 CN, —(CH 2 ) 11 OC(O)NH 2 , —(CH 2 ) 11 COOEt, —C(O)(CH 2 ) 9 CH 3 , —(CH 2 ) 5 C(O)N(CH 2 CH 2 ) 2 O, C 3 -C 7 cycloalkyl, —C 6 H 5 , 2-pyrrolyl, -3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, and 3-furanyl, the phenyl being substituted with one or more halo, methyl, methoxyl, hydroxyl, methoxycarbonyl or trifluoromethyl groups;
R 8 is selected from the group consisting of —H, C 1 -C 11 straight chain alkyl, —(CH 2 ) 4 COOEt, and —C 6 H 5 ;
when R 7 is other than 2-pyrrolyl, then R 9 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 3 , and —CH 2 CH 2 CH 3 ;
when R 7 is 2-pyrrolyl, then R 9 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , and —OCH 3 ;
R 10 is selected from the group consisting of C 1 -C 4 straight or branched chain alkyl and —C 6 H 5 ;
R 11 and R 12 are independently selected from the group consisting of —CH 3 , —CH 2 CH 3 , and —C 3 H 7 ;
R 16 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 2 CH 3 , and —(CH 2 ) 6 CH 3 ; and
R 17 is selected from the group consisting of —H, —CN, —COOMe, —COOEt, and —COOH.
15 . The method of claim 14 , wherein the compound of Formula (V) has the Formula:
or a pharmaceutically acceptable salt thereof.
16 . The method of claim 14 , wherein the compound of Formula (V) has the Formula:
or a pharmaceutically acceptable salt thereof.
17 . A method for inhibiting the replication or infectivity of a virus, comprising a contacting a virus or a virus-infected cell with an effective amount of a compound of Formula (V):
or a pharmaceutically acceptable salt thereof, wherein, in the compound of Formula (V):
each R 1 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 3 , —CH 2 C 6 H 5 , —C(O)OC(CH 3 ) 3 , —C(O)OCH 2 C 6 H 5 , and —C(O)CH 3 ;
R 2 is selected from the group consisting of —H, C 1 -C 12 straight chain alkyl, —CH 2 C 6 H 5 , —SiR 10 R 11 R 12 , —C(O)CH 3 , —C(O)C 6 H 5 , -2-tetrahydropyranyl, —OCH 2 OCH 3 , and —C(O)OCH 2 CCl 3 ;
R 7 is selected from the group consisting of —H, C 1 -C 15 straight chain alkyl, —(CH 2 ) 9 CH═CH 2 , —(CH 2 ) 6 F, —(CH 2 ) 5 OC 6 H 5 , —(CH 2 ) 6 OH, —(CH 2 ) 7 CN, —CH 2 CH 2 C 6 H 5 , —(CH 2 ) 4 COOH, —(CH 2 ) 5 COOH, —(CH 2 ) 5 COOMe, —(CH 2 ) 11 COOH, —(CH 2 ) 12 COOH, —(CH 2 ) 12 OH, —(CH 2 ) 13 OH, —(CH 2 ) 11 CN, —(CH 2 ) 11 OC(O)NH 2 , —(CH 2 ) 11 COOEt, —C(O)(CH 2 ) 9 CH 3 , —(CH 2 ) 5 C(O)N(CH 2 CH 2 ) 2 O, C 3 -C 7 cycloalkyl, —C 6 H 5 , 2-pyrrolyl, -3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, and 3-furanyl, the phenyl being substituted with one or more halo, methyl, methoxyl, hydroxyl, methoxycarbonyl or trifluoromethyl groups;
R 8 is selected from the group consisting of —H, C 1 -C 11 straight chain alkyl, —(CH 2 ) 4 COOEt, and —C 6 H 5 ;
when R 7 is other than 2-pyrrolyl, then R 9 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 3 , and —CH 2 CH 2 CH 3 ;
when R 7 is 2-pyrrolyl, then R 9 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , and —OCH 3 ;
R 10 is selected from the group consisting of C 1 -C 4 straight or branched chain alkyl and —C 6 H 5 ;
R 11 and R 12 are independently selected from the group consisting of —CH 3 , —CH 2 CH 3 , and —C 3 H 7 ;
R 16 is selected from the group consisting of —H, —CH 3 , —CH 2 CH 2 CH 3 , and —(CH 2 ) 6 CH 3 ; and
R 17 is selected from the group consisting of —H, —CN, —COOMe, —COOEt, and —COOH.
18 . The method of claim 17 , wherein the compound of Formula (V) has the Formula:
or a pharmaceutically acceptable salt thereof.
19 . The method of claim 17 , wherein the compound of Formula (V) has the Formula:
or a pharmaceutically acceptable salt thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.